US OptionsDetailed Quotes

MEIP241220C2000

Watchlist

1.70
0.000.00%

15min DelayClose Nov 29 13:00 ET

0.00High0.00Low

MEI Pharma Stock Discussion

Jaguar8

Oct 28 00:23

Watch tomorrow. 8K filed Friday. Biotech low float, sold assets, initial $500K up to $60M upon reaching certain milestones

$MEI Pharma (MEIP.US)$
“On October 22, 2024 (the “Closing Date”), MEI Pharma, Inc., a Delaware corporation (the “Company”), and Aardvark Therapeutics, Inc., a Delaware corporation (the “Purchaser”), entered into an Asset Purchase Agreement (the “Asset Purchase Agreement”), pursuant to which the Company sold its rights, title and interest in and to certain assets related to ME-...

Stock_Drift

Oct 25 15:54

After Hours Ticks. 4:52pm

$Pasithea Therapeutics (KTTA.US)$ $Gulf Resources (GURE.US)$ $Sadot (SDOT.US)$ $Edesa Biotech (EDSA.US)$ $Crown Electrokinetics (CRKN.US)$ $P3 Health Partners (PIII.US)$ $MIRA Pharmaceuticals (MIRA.US)$ $Sky Quarry (SKYQ.US)$ $FGI Industries (FGI.US)$ $Check-Cap (CHEK.US)$ $MEI Pharma (MEIP.US)$ $Healthcare Triangle (HCTI.US)$ $Pixie Dust Technologies(Delisted) (PXDT.US)$

George Soros II

Oct 25 15:17

$MEI Pharma (MEIP.US)$
Wohooo

Jaguar8

Apr 11 07:05

$MEI Pharma (MEIP.US)$
NEWS
MEI Pharma Reports Initial Data from Clinical Study Evaluating ME-344 in Combination with Bevacizumab (Avastin®) in Relapsed Metastatic Colorectal Cancer Patients
MEI Pharma, Inc. reports positive results from the ongoing Phase 1b study of ME-344 in combination with bevacizumab for relapsed metastatic colorectal cancer. 25% of patients had no disease progression at Week 16, exceeding the threshold to add more patients. The combination was well-tolerated, leading to the...